Details of the Drug Reposition

General Information of This Drug (ID: DMHPZ8G)

Drug Name
CD20-Specific CAR T Cells   DMHPZ8G
Drug Type
CAR T Cell Therapy

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
5 Phase 1/2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Large cell lymphoma DISYZHCP 2A80.Z Phase 1/2 [1]
Lymphoma DISN6V4S 2A80-2A86 Phase 1/2 [1]
Chronic lymphocytic leukaemia DISEXWC3 2A82.0 Phase 1/2 [1]
Mantle cell lymphoma DISFREOV 2A85.5 Phase 1/2 [1]
Non-hodgkin lymphoma DISS2Y8A 2B33.5 Phase 1/2 [1]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT03277729) A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas